Pharm Exec: Navigating the Financial Meltdown for Biopharma (Young & Partners article – August 2022 issue)digitalstudios2022-08-12T18:23:33+00:00August 12th, 2022|Featured|
Disruptions Suppress M&A and Financing (ICIS Chemical Business (May 20-26, 2022 issue)digitalstudios2022-05-25T12:21:37+00:00May 25th, 2022|Featured, Our Publications|
Medical Device Industry Merger and Acquisition Trendsdigitalstudios2022-03-30T18:01:06+00:00April 16th, 2021|Issues & Trends, Medical Device Industry - Merger and Acquisition Trends|
Medical Device Industry Debt and Equity Financing Trendsdigitalstudios2022-03-30T18:04:00+00:00April 16th, 2021|Issues & Trends, Medical Device Industry - Debt and Equity Financing Trends|
Medical Device Industry Stock Market Trendsdigitalstudios2022-03-30T17:54:14+00:00March 5th, 2021|Issues & Trends, Medical Device Industry - Stock Market Trends|
Chemical Industry Financial Critical Massdigitalstudios2021-03-05T09:00:42+00:00March 5th, 2021|Chemical Industry - Financial Critical Mass, Issues & Trends|
Pharmaceutical Industry Stock Market Trendsdigitalstudios2022-03-30T17:35:51+00:00March 5th, 2021|Issues & Trends, Pharmaceutical Industry - Stock Market Trends|
Biotechnology Industry Stock Market Trendsdigitalstudios2022-03-30T17:41:34+00:00March 5th, 2021|Biotechnology Industry - Stock Market Trends, Issues & Trends|
Pharmaceutical Industry Debt and Equity Financing Trendsdigitalstudios2022-03-30T17:38:31+00:00March 5th, 2021|Issues & Trends, Pharmaceutical Industry - Debt and Equity Financing Trends|
Pharmaceutical Industry Merger and Acquisition Trendsdigitalstudios2022-03-30T17:31:13+00:00March 5th, 2021|Issues & Trends, Pharmaceutical Industry - Merger and Acquisition Trends|
